PL2097444T3 - Sposób zastosowania transgenicznego zwierzęcia o podwyższonej odpowiedzi immunologicznej - Google Patents

Sposób zastosowania transgenicznego zwierzęcia o podwyższonej odpowiedzi immunologicznej

Info

Publication number
PL2097444T3
PL2097444T3 PL07859364T PL07859364T PL2097444T3 PL 2097444 T3 PL2097444 T3 PL 2097444T3 PL 07859364 T PL07859364 T PL 07859364T PL 07859364 T PL07859364 T PL 07859364T PL 2097444 T3 PL2097444 T3 PL 2097444T3
Authority
PL
Poland
Prior art keywords
immune response
enhanced
animal
human animal
transgenic animal
Prior art date
Application number
PL07859364T
Other languages
English (en)
Inventor
Zsuzsanna Bösze
Imre Kacskovics
Judit Cervenak
László Hiripi
Balázs Bender
Original Assignee
Agricultural Biotechnology Center
Eoetvoes Lorand Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2097444(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from HUE06000870 external-priority patent/HU0600870D0/hu
Application filed by Agricultural Biotechnology Center, Eoetvoes Lorand Univ filed Critical Agricultural Biotechnology Center
Publication of PL2097444T3 publication Critical patent/PL2097444T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL07859364T 2006-11-24 2007-11-23 Sposób zastosowania transgenicznego zwierzęcia o podwyższonej odpowiedzi immunologicznej PL2097444T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HUE06000870 HU0600870D0 (en) 2006-11-24 2006-11-24 Transgenic animal with increased immunoglobulin level and method for the preparation thereof
HUE07000534 2007-08-14
PCT/IB2007/054770 WO2008062383A2 (en) 2006-11-24 2007-11-23 Transgenic animal with enhanced immune response and method for the preparation thereof
EP07859364A EP2097444B1 (en) 2006-11-24 2007-11-23 Method using a transgenic animal with enhanced immune response

Publications (1)

Publication Number Publication Date
PL2097444T3 true PL2097444T3 (pl) 2011-11-30

Family

ID=46846408

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07859364T PL2097444T3 (pl) 2006-11-24 2007-11-23 Sposób zastosowania transgenicznego zwierzęcia o podwyższonej odpowiedzi immunologicznej

Country Status (11)

Country Link
US (2) US20100041743A1 (pl)
EP (3) EP2559701B1 (pl)
JP (2) JP5752355B2 (pl)
CN (1) CN101595128B (pl)
AT (1) ATE513852T1 (pl)
AU (2) AU2007323049B2 (pl)
CA (1) CA2670389C (pl)
DK (1) DK2097444T3 (pl)
HU (1) HU0700534D0 (pl)
PL (1) PL2097444T3 (pl)
WO (1) WO2008062383A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2784953C (en) * 2009-12-21 2018-05-22 Regeneron Pharmaceuticals, Inc. Humanized fc.gamma.r mice
SMT202200205T1 (it) 2011-10-28 2022-07-21 Regeneron Pharma Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii
EP2773952B1 (en) * 2011-11-03 2019-01-09 University of Iowa Research Foundation Transgenic pig models of cystic fibrosis
EP3699190B9 (en) * 2013-02-22 2023-10-04 Regeneron Pharmaceuticals, Inc. Murine cell expressing humanized major histocompatibility complex
WO2015036004A1 (en) * 2013-09-13 2015-03-19 Immunogenes Ag Method for preparing an improved atg composition
CN104237533A (zh) * 2014-09-23 2014-12-24 中国科学院东北地理与农业生态研究所 一种初步筛选可用于繁殖后代转基因母羊的方法
IL314733A (en) * 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
EP4287828A4 (en) * 2021-02-02 2025-01-15 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric fcrn
CN116076438B (zh) * 2023-03-21 2024-01-30 湖南中医药大学 类风湿关节炎合并间质性肺病动物模型及其构建方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2690956B2 (ja) 1987-08-22 1997-12-17 三井東圧化学株式会社 生体由来のタンパク質
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5675063A (en) * 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1999013092A1 (en) * 1997-09-11 1999-03-18 The Public Health Research Institute Of The City Of New York, Inc. Enhancement of mucosal antibody responses by interleukin-6
US6249816B1 (en) * 1998-07-22 2001-06-19 Nokia Telecommunications, Oy NBR pool for SIMA network
US7074983B2 (en) 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
US20060272036A1 (en) * 2000-02-03 2006-11-30 Lennart Hammarstrom Ruminant mhc class-i-like fc receptors
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
WO2002043658A2 (en) * 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
DE602004030451D1 (de) 2003-07-15 2011-01-20 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm-produktion
WO2005087811A2 (en) 2004-03-10 2005-09-22 Creighton University Estrogen receptors and methods of use
CN103710371B (zh) 2005-08-03 2017-03-01 人类多克隆治疗股份有限公司 表达人源化免疫球蛋白的转基因动物中b细胞凋亡的抑制
EP1790716A1 (en) 2005-11-23 2007-05-30 UMC Utrecht Holding B.V. Uses of the FcRn receptor

Also Published As

Publication number Publication date
EP2097444A2 (en) 2009-09-09
ATE513852T1 (de) 2011-07-15
CA2670389A1 (en) 2008-05-29
EP2559701A1 (en) 2013-02-20
US20100041743A1 (en) 2010-02-18
JP2013215194A (ja) 2013-10-24
DK2097444T3 (da) 2011-08-29
CN101595128B (zh) 2014-11-26
WO2008062383A3 (en) 2008-08-14
US20130109087A1 (en) 2013-05-02
AU2007323049B2 (en) 2012-03-15
WO2008062383A2 (en) 2008-05-29
JP2010510773A (ja) 2010-04-08
EP2097444B1 (en) 2011-06-22
AU2007323049A1 (en) 2008-05-29
JP5752355B2 (ja) 2015-07-22
AU2012203243A1 (en) 2012-06-21
AU2007323049A8 (en) 2011-07-28
CA2670389C (en) 2014-12-09
EP2386573A1 (en) 2011-11-16
HU0700534D0 (en) 2007-10-29
HK1134305A1 (en) 2010-04-23
EP2559701B1 (en) 2016-04-20
CN101595128A (zh) 2009-12-02

Similar Documents

Publication Publication Date Title
PL2097444T3 (pl) Sposób zastosowania transgenicznego zwierzęcia o podwyższonej odpowiedzi immunologicznej
ES2849349T3 (es) Anticuerpos de cadena ligera modificados mediante ingeniería con histidina y roedores modificados genéticamente para la generación de los mismos
DK1354034T3 (da) Transgene transchromosomale gnavere til fremstilling af humane antistoffer
EP3046412B1 (en) Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
SG10201408500RA (en) Antibody producing non-human mammals
ECSP12011698A (es) Anticuerpos cea
NZ577828A (en) Human antibodies that bind human il-12 and methods for producing
MX355726B (es) Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii.
DK2152880T3 (da) Sammensætninger og fremgangsmåder til hæmning af endogene immunoglobulingener og produktion af transgene, humane idiotype antistoffer
WO2006117699A3 (en) Transgenic animals and methods of making recombinant antibodies
CR9236A (es) Moleculas de union al antigeno que fijan eger, vectores que las codifican y usos de las mismas
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
DK1425389T3 (da) Interleukin-15-(IL-15)-specifikke humane antistoffer
DK1210374T3 (da) Humane, monoklonale antistoffer over for prostataspecifikt membranantigen
WO2008145140A3 (en) Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
US20130217043A1 (en) Humanized transgenic mouse model
WO2006047367A3 (en) Suppression of endogenous immunoglubolin expression in non-human transgenic animals
WO2008153743A3 (en) Compositions and methods for cancer gene discovery
CN103571872A (zh) 一种能够表达人抗体的转基因动物的制备方法
PT1709073E (pt) Substância que se liga ao receptor fc iib de igg humano (fcgamariib)
Conner et al. A precisely humanized FCRN transgenic mouse for preclinical pharmacokinetics studies
Gjertsson et al. Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis
Kacskovics et al. Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies
SG142293A1 (en) Method for producing anti-idiotypic antibodies
DE60331416D1 (de) Transgene mäuse, die prkag3 exprimieren